HMGB1 and acute respiratory distress syndrome: Indeed, our data strongly support that anti‐HMGB1 therapy significantly prolongs the therapeutic window of experimental APAP‐ALI (Fig. 4) and would likely be invaluable in treatment of late‐presenting patients or in patients that do not respond satisfactorily to NAC.